Clinical Trial

Clinical Significance of Liquid Biopsy in Brain Tumor Patients: a 5-ALA Guided Approach

Study acronym: FLUO-LB
Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated February 19, 2026 (before its estimated May 2026 completion). Its status may not reflect the trial's current state.
Summary
Glioblastoma (GBM) is the most common and lethal primary brain tumor. Identifying blood biomarkers that reflect the tumor's status is a major unmet need for optimal clinical management. 5-ALA (5-Aminolevulinic Acid) administration leads to the accumulation of fluorescent Protoporphyrin IX (PpIX) in GBM cells, allowing identification during surgery. This project aims to leverage 5-ALA induced fluorescence to maximize the informational power of plasma liquid biopsy as a tool for diagnosis, post-treatment follow-up, and as a prognostic tool in patients with GBM.
Trial Details
NCT Number NCT07420543
Lead Sponsor Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta
Collaborators: University of Milan, Università degli Studi del Piemonte Orientale Amedeo Avogadro
Conditions Brain Tumors and/or Solid Tumors Including, Glioblastoma, Glioblastoma (GBM), Glioblastoma - Category
Enrollment 30 participants
Start Date 2017-01-18
Primary Completion 2026-05 (estimated)
Study Completion 2027-05 (estimated)
Updated on ClinicalTrials.gov 2026-02-19